Hopp til hovedinnhold
Nyttige tiltak for den med muskeldystrofi er moderat fysisk trening.
Nyttige tiltak for den med muskeldystrofi er moderat fysisk trening.

Duchennes muskeldystrofi

Muskeldystrofi er betegnelse på tilstander hvor musklene ikke utvikler seg som de skal, og blir tynne og svake. Duchennes muskeldystrofi er den hyppigste typen.

Sist revidert:
QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/barn/arvelige-og-medfodte-tilstander/duchennes-muskeldystrofi/ 

Hva er muskeldystrofi?

Årsak

Symptomer

Diagnosen

Behandling

Prognose

Nasjonale tjenester

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Duchenne muskeldystrofi. Referanselisten for dette dokumentet vises nedenfor.

  1. Crisafulli S, Sultana J, Fontana A, et al. Global epidemiology of Duchenne muscular dystrophy. Orphanet J Rare Dis. 2020;15(1):141. PMID: 32503598 PubMed 
  2. Fox H, Millington L, Mahabeer I, van Ruiten H. Duchenne muscular dystrophy. BMJ 2020; 368: l7012. pmid:31974125 PubMed 
  3. Houwen-van Opstal SLS, Heutinck L, Jansen M, et al. Occurrence of symptoms in different stages of Duchenne muscular dystrophy and their impact on social participation. Muscle Nerve 2021; 64: 701-709. pmid:34453345 PubMed 
  4. Annexstad EJ, Lund-Pedersen I, Rasmussen M. Duchenne muscular dystrophy. Tidsskr Nor Legeforen 2014. pmid:25096430 PubMed 
  5. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol2018;17:251-67. PMID: 29395989 PubMed 
  6. Spurney CF, Ascheim D, Charnas L, et al. Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel. Heart 2021. doi:10.1136/openhrt-2021-001592 DOI 
  7. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol2018;17:347-61. PMID: 29395990 PubMed 
  8. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol2018;17:445-55. PMID: 29398641 PubMed 
  9. Bach JR. Muscular dystrophies. BestPractice, last updated Nov 19, 2014.
  10. Andersen G, Prahm KP, Dahlqvist JR, et al. Aerobic training and postexercise protein in facioscapulohumeral muscular dystrophy. Neurology 2015; 85: 396-403. doi:http:/​/​dx.​doi.​org/​10.​1212/​WNL.​0000000000001808
  11. Guglieri M, Bushby K, McDermott MP, et al. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy A Randomized Clinical Trial. JAMA 2022; 327: 1456-68. pmid:35381069 PubMed 
  12. McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 2018; 391: 451-61. pmid:29174484 PubMed 
  13. Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD003725. DOI: 10.1002/14651858.CD003725.pub4 DOI 
  14. Gloss D, Moxley RT, Ashwal S, et al. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy. Neurology February 2, 2016 vol. 86 no. 5 465-472 . doi:10.​1212/​WNL.​0000000000002337
  15. McDonald CM, Campbell C, Torricelli RE, et al. Clinical Evaluator Training Group; ACT DMD Study Group. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Sep 23;390(10101):1489-1498 . pmid:28728956 PubMed 
  16. Duboc D, Meune C, Pierre B, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007; 154: 596-602. PubMed 
  17. Cheuk DKL, Wong V, Wraige E, Baxter P, Cole A. Surgery for scoliosis in Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No.: CD005375. DOI: 10.1002/14651858.CD005375.pub4 DOI 
  18. Annane D, Orlikowski D, Chevret S. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No.: CD001941. DOI: 10.1002/14651858.CD001941.pub3 DOI 
  19. Wang M, Birnkrant DJ, Super DM, et al. Progressive left ventricular dysfunction and long-term outcomes in patients with Duchenne muscular dystrophy receiving cardiopulmonary therapies. Open Heart 2018. doi:10.1136/openhrt-2018-000783 DOI